A groundbreaking research survey of 500 biopharma executives reveals why life sciences companies need to rethink their data platforms. Replatforming scientific data to an open cloud platform while transforming the data to FAIR (Findable, Accessible, Interoperable, Reusable) principles impacts three key industry drivers:
- Speed: Learning from experiments faster, reducing time to market for final molecules
- Cost: Improving productivity, increasing operational efficiency, increasing return on investment (ROI)
- Risk: Improving safety, reducing errors, improving compliance with regulatory requirements
Executives say that replatforming scientific data to an open cloud platform would accelerate time to market by 65%.
Each one-day delay in getting a drug or therapeutic to market costs biopharmas an average of $1.26 million in lost revenue and/or loss of first-mover advantage.
Slowness to market and lost revenue are not the end of the story. Cloud ‘laggards’ spend 3.7X more on inefficient infrastructure compared to cloud leaders.
Download this report to calibrate your scientific data strategy. Learn how utilizing FAIR data in the cloud is a game changer.
